Mersana Therapeutics Inc Stock Price, News & Analysis

Mersana Therapeutics (NASDAQ: MRSN) announced positive interim Phase 1 clinical data for their B7-H4-directed Dolasynthen ADC, Emi-Le (XMT-1660), at ASCO 2025. The drug showed a 31% confirmed objective response rate across B7-H4 high tumors at intermediate doses, and 44% confirmed ORR in patients with ≤4 prior lines of therapy. Notable results include a 56% ORR in ACC-1 patients regardless of dose and B7-H4 expression. The safety profile remained consistent with previous reports, with no new safety signals observed. The trial focused on various cancers including triple-negative breast cancer, HR+/HER2- breast cancer, ovarian cancer, endometrial cancer, and ACC-1. The FDA has granted two Fast Track designations for Emi-Le in advanced/metastatic triple-negative breast cancer and HER2 low/negative breast cancer post-topo-1 ADC treatments.

Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 2:00 p.m. ET, and deliver a presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:00 p.m. ET. Both events will be webcast live and available on Mersana's website, with replays accessible for approximately 90 days.

Mersana Therapeutics (NASDAQ: MRSN) reported Q1 2025 financial results and provided updates on its clinical programs. The company's lead drug Emi-Le showed promising results in treating cancer patients with B7-H4 high tumors, achieving a 31% objective response rate across tumor types. In triple-negative breast cancer (TNBC) patients with B7-H4 high expression who received prior topo-1 ADC treatment, Emi-Le demonstrated a 29% response rate with median PFS of 16.0 weeks. The company's financial position shows $102.3 million in cash as of March 31, 2025, with runway expected into mid-2026. Q1 2025 resulted in a net loss of $24.1 million ($0.19 per share) compared to $19.3 million in Q1 2024. Mersana plans to report initial expansion cohort data in H2 2025.

Mersana Therapeutics (MRSN) presented updated clinical data for Emi-Le, their B7-H4-directed Dolasynthen ADC, at ESMO Breast Cancer 2025. The data showed an increased ORR of 31% across tumor types in B7-H4 high tumors at intermediate doses. For TNBC patients with B7-H4 high expression who received ≤4 prior treatments, the data revealed a 29% ORR, median PFS of 16.0 weeks, and median OS not yet reached. The company is advancing two dose expansion cohorts: "Dose A" at 67.4 mg/m² Q4W and "Dose B" starting at 44.5 mg/m² with escalation to 80 mg/m². Initial expansion data is expected in H2 2025. Financially, Mersana reported $102.3 million in cash as of March 31, 2025, with runway into mid-2026. Q1 2025 showed collaboration revenue of $2.8 million and a net loss of $24.1 million ($0.19 per share).

Mersana Therapeutics (NASDAQ: MRSN) announced a strategic restructuring plan to extend its cash runway into mid-2026. The plan includes a 55% workforce reduction across functions, expected to be completed by Q3 2025. The company will reduce research activities and eliminate internal pipeline development efforts to focus on developing Emi-Le (emiltatug ledadotin), their B7-H4-directed Dolasynthen ADC targeting triple-negative breast cancer. Mersana will continue supporting Phase 1 dose escalation work for XMT-2056 and maintain ongoing collaborations. The restructuring decision comes amid challenging macro-economic conditions as the company aims to achieve additional clinical milestones with Emi-Le.

Mersana Therapeutics (NASDAQ: MRSN) announced upcoming presentations of their B7-H4-directed Dolasynthen ADC, emiltatug ledadotin (Emi-Le), at the ASCO 2025 Annual Meeting from May 30-June 3, 2025. The presentations include:

1. An oral presentation on Phase 1 dose escalation data across tumor types by Dr. Erika Hamilton on June 2, 2025

2. A poster presentation on the ongoing Phase 1 dose expansion trial in triple negative breast cancer (TNBC) patients by Dr. Hyo Han

Initial clinical data from December 2024 showed Emi-Le was generally well tolerated with confirmed objective responses across all enrolled tumor types. The FDA has granted two Fast Track designations for Emi-Le: one for advanced/metastatic TNBC and another for HER2 low/negative breast cancer patients who received prior topo-1 ADC treatment.

Mersana Therapeutics (NASDAQ:MRSN) has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company granted a restricted stock unit (RSU) award to one new employee who joined in March 2025. The award consists of 26,790 shares of common stock.

The RSU award will vest in four equal annual installments starting from February 15, 2025, contingent on the employee's continued service with Mersana. The grant is subject to Mersana's 2022 Inducement Stock Incentive Plan and RSU agreement terms.

Mersana Therapeutics (NASDAQ: MRSN) announced upcoming presentation of Phase 1 clinical data for emiltatug ledadotin (Emi-Le) at ESMO Breast Cancer 2025 Annual Congress in Munich. The presentation will focus on clinical activity in patients with triple negative breast cancer (TNBC) who received prior topoisomerase-1 inhibitor ADC treatment.

Initial clinical data from December 13, 2024, showed Emi-Le was generally well-tolerated with a differentiated safety profile. The B7-H4-directed Dolasynthen ADC demonstrated confirmed objective responses across all enrolled tumor types. The FDA has granted two Fast Track designations for Emi-Le: one for advanced/metastatic TNBC and another for advanced/metastatic breast cancer in patients with HER2-low or HER2-negative disease who received prior topo-1 ADC.

Mersana Therapeutics (NASDAQ: MRSN) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical development programs. The company announced positive initial Phase 1 data for Emi-Le, its B7-H4-targeting ADC candidate, and received an additional Fast Track designation from the FDA.

Key financial metrics for Q4 2024:

• Cash position: $134.6 million as of December 31, 2024
• Collaboration revenue: $16.4 million (up from $10.7 million in Q4 2023)
• Net loss: $14.1 million ($0.11 per share)
• R&D expenses: $22.3 million
• G&A expenses: $8.9 million

For full year 2024, the company reported collaboration revenue of $40.5 million and a net loss of $69.2 million ($0.56 per share). Mersana expects its current capital resources to support operations into 2026.